Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.44
MDT's Cash-to-Debt is ranked lower than
75% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. MDT: 0.44 )
Ranked among companies with meaningful Cash-to-Debt only.
MDT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 0.79 Max: 7.76
Current: 0.44
0.21
7.76
Equity-to-Asset 0.56
MDT's Equity-to-Asset is ranked lower than
67% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MDT: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
MDT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.63 Max: 0.79
Current: 0.56
0.48
0.79
Debt-to-Equity 0.51
MDT's Debt-to-Equity is ranked lower than
71% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. MDT: 0.51 )
Ranked among companies with meaningful Debt-to-Equity only.
MDT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.28 Max: 0.84
Current: 0.51
0.03
0.84
Debt-to-EBITDA 2.72
MDT's Debt-to-EBITDA is ranked lower than
64% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. MDT: 2.72 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MDT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.85  Med: 2.2 Max: 6.61
Current: 2.72
1.85
6.61
Interest Coverage 5.53
MDT's Interest Coverage is ranked lower than
82% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 66.37 vs. MDT: 5.53 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s Interest Coverage Range Over the Past 10 Years
Min: 4.3  Med: 9.63 Max: 12.85
Current: 5.53
4.3
12.85
Piotroski F-Score: 8
Altman Z-Score: 2.93
Beneish M-Score: -2.48
WACC vs ROIC
4.85%
5.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 21.18
MDT's Operating Margin % is ranked higher than
88% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. MDT: 21.18 )
Ranked among companies with meaningful Operating Margin % only.
MDT' s Operating Margin % Range Over the Past 10 Years
Min: 20.67  Med: 25.72 Max: 29.47
Current: 21.18
20.67
29.47
Net Margin % 10.36
MDT's Net Margin % is ranked higher than
74% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. MDT: 10.36 )
Ranked among companies with meaningful Net Margin % only.
MDT' s Net Margin % Range Over the Past 10 Years
Min: 10.36  Med: 16.1 Max: 22.35
Current: 10.36
10.36
22.35
ROE % 6.13
MDT's ROE % is ranked higher than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. MDT: 6.13 )
Ranked among companies with meaningful ROE % only.
MDT' s ROE % Range Over the Past 10 Years
Min: 6.13  Med: 16.42 Max: 22.29
Current: 6.13
6.13
22.29
ROA % 3.22
MDT's ROA % is ranked higher than
61% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -0.26 vs. MDT: 3.22 )
Ranked among companies with meaningful ROA % only.
MDT' s ROA % Range Over the Past 10 Years
Min: 3.22  Med: 8.73 Max: 11.99
Current: 3.22
3.22
11.99
ROC (Joel Greenblatt) % 78.46
MDT's ROC (Joel Greenblatt) % is ranked higher than
91% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 3.87 vs. MDT: 78.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.55  Med: 70.37 Max: 79.72
Current: 78.46
51.55
79.72
3-Year Revenue Growth Rate 6.20
MDT's 3-Year Revenue Growth Rate is ranked higher than
63% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. MDT: 6.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MDT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.2  Med: 13.9 Max: 18.6
Current: 6.2
4.2
18.6
3-Year EBITDA Growth Rate 12.00
MDT's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 7.50 vs. MDT: 12.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MDT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3.7  Med: 16.5 Max: 26.5
Current: 12
-3.7
26.5
3-Year EPS without NRI Growth Rate -2.00
MDT's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 7.80 vs. MDT: -2.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MDT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 15.6 Max: 27.1
Current: -2
-9.7
27.1
GuruFocus has detected 7 Warning Signs with Medtronic PLC MDT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MDT's 30-Y Financials

Financials (Next Earnings Date: 2018-08-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

MDT Guru Trades in Q3 2017

Jim Simons 6,397,513 sh (+1374.08%)
Paul Tudor Jones 58,839 sh (+200.43%)
Diamond Hill Capital 3,441,700 sh (+28.44%)
Robert Olstein 111,000 sh (+21.78%)
T Rowe Price Equity Income Fund 3,100,000 sh (+14.53%)
John Buckingham 21,123 sh (+7.08%)
Dodge & Cox 12,147,095 sh (+4.86%)
Caxton Associates 7,200 sh (+4.35%)
Ken Fisher 188,912 sh (+2.80%)
Mairs and Power 3,554,055 sh (+1.97%)
Manning & Napier Advisors, Inc 5,289,068 sh (+1.75%)
Pioneer Investments 4,937,553 sh (+0.95%)
Jeff Auxier 148,248 sh (+0.85%)
Signature Select Canadian Fund 64,100 sh (+0.79%)
HOTCHKIS & WILEY 2,236,797 sh (+0.41%)
Vanguard Health Care Fund 16,509,984 sh (unchged)
David Carlson 970,000 sh (unchged)
First Eagle Investment 1,434 sh (unchged)
Bill Nygren 2,440,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 70,571 sh (unchged)
NWQ Managers 3,339 sh (-2.71%)
PRIMECAP Management 9,256,010 sh (-6.21%)
Jeremy Grantham 4,075,480 sh (-6.80%)
Mario Gabelli 23,820 sh (-7.21%)
Barrow, Hanley, Mewhinney & Strauss 16,574,247 sh (-15.80%)
Joel Greenblatt 316,892 sh (-28.21%)
» More
Q4 2017

MDT Guru Trades in Q4 2017

First Pacific Advisors 5,250 sh (New)
Ray Dalio 25,152 sh (New)
Steven Cohen 1,589,025 sh (New)
Caxton Associates 16,777 sh (+133.01%)
Dodge & Cox 18,284,758 sh (+50.53%)
Bill Nygren 3,190,000 sh (+30.74%)
Mario Gabelli 29,314 sh (+23.06%)
John Buckingham 25,150 sh (+19.06%)
Diamond Hill Capital 4,066,070 sh (+18.14%)
HOTCHKIS & WILEY 2,480,897 sh (+10.91%)
Pioneer Investments 5,324,932 sh (+7.85%)
Robert Olstein 117,000 sh (+5.41%)
Jeff Auxier 155,333 sh (+4.78%)
T Rowe Price Equity Income Fund 3,200,000 sh (+3.23%)
Mairs and Power 3,640,623 sh (+2.44%)
Jeremy Grantham 4,081,011 sh (+0.14%)
First Eagle Investment 1,434 sh (unchged)
Steven Cohen 500,000 sh (unchged)
NWQ Managers Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Barrow, Hanley, Mewhinney & Strauss 15,698,567 sh (-5.28%)
PRIMECAP Management 8,753,098 sh (-5.43%)
Vanguard Health Care Fund 15,408,784 sh (-6.67%)
Ken Fisher 164,198 sh (-13.08%)
David Carlson 800,000 sh (-17.53%)
Paul Tudor Jones 43,331 sh (-26.36%)
Joel Greenblatt 204,272 sh (-35.54%)
Jim Simons 1,432,441 sh (-77.61%)
» More
Q1 2018

MDT Guru Trades in Q1 2018

First Pacific Advisors 16,400 sh (+212.38%)
Joel Greenblatt 427,957 sh (+109.50%)
HOTCHKIS & WILEY 3,862,825 sh (+55.70%)
Ken Fisher 216,956 sh (+32.13%)
Jeremy Grantham 4,446,710 sh (+8.96%)
Diamond Hill Capital 4,227,340 sh (+3.97%)
Jeff Auxier 161,248 sh (+3.81%)
T Rowe Price Equity Income Fund 3,320,000 sh (+3.75%)
Dodge & Cox 18,721,632 sh (+2.39%)
Mairs and Power 3,668,495 sh (+0.77%)
Vanguard Health Care Fund 15,408,784 sh (unchged)
Bill Nygren 3,190,000 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
First Eagle Investment Sold Out
Signature Select Canadian Fund Sold Out
John Buckingham 25,086 sh (-0.25%)
Robert Olstein 116,000 sh (-0.85%)
Barrow, Hanley, Mewhinney & Strauss 15,240,620 sh (-2.92%)
PRIMECAP Management 8,179,292 sh (-6.56%)
Caxton Associates 13,692 sh (-18.39%)
Mario Gabelli 23,332 sh (-20.41%)
Pioneer Investments 4,086,932 sh (-23.25%)
David Carlson 560,000 sh (-30.00%)
Paul Tudor Jones 22,290 sh (-48.56%)
Steven Cohen 741,199 sh (-53.36%)
» More
Q2 2018

MDT Guru Trades in Q2 2018

Eaton Vance Worldwide Health Sciences Fund 117,565 sh (New)
Joel Greenblatt 651,133 sh (+52.15%)
Pioneer Investments 5,458,335 sh (+33.56%)
Steven Cohen 823,622 sh (+11.12%)
Ken Fisher 226,743 sh (+4.51%)
T Rowe Price Equity Income Fund 3,460,000 sh (+4.22%)
Mario Gabelli 23,744 sh (+1.77%)
Dodge & Cox 18,738,182 sh (+0.09%)
John Buckingham 25,106 sh (+0.08%)
David Carlson 560,000 sh (unchged)
Caxton Associates Sold Out
PRIMECAP Management 8,162,952 sh (-0.20%)
Jeff Auxier 159,098 sh (-1.33%)
Barrow, Hanley, Mewhinney & Strauss 14,589,501 sh (-4.27%)
Diamond Hill Capital 4,018,635 sh (-4.94%)
Mairs and Power 3,464,399 sh (-5.56%)
Vanguard Health Care Fund 14,533,984 sh (-5.68%)
HOTCHKIS & WILEY 3,627,625 sh (-6.09%)
Jeremy Grantham 3,568,527 sh (-19.75%)
Robert Olstein 86,000 sh (-25.86%)
First Pacific Advisors 8,950 sh (-45.43%)
Paul Tudor Jones 3,507 sh (-84.27%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2018-06-30 Add 0.09%$77.48 - $87.83 $ 90.609%18,738,182
Barrow, Hanley, Mewhinney & Strauss 2018-06-30 Reduce -4.27%0.08%$77.48 - $87.83 $ 90.609%14,589,501
Vanguard Health Care Fund 2018-06-30 Reduce -5.68%0.16%$77.48 - $87.83 $ 90.609%14,533,984
HOTCHKIS & WILEY 2018-06-30 Reduce -6.09%0.07%$77.48 - $87.83 $ 90.609%3,627,625
T Rowe Price Equity Income Fund 2018-06-30 Add 4.22%0.06%$77.48 - $87.83 $ 90.609%3,460,000
Joel Greenblatt 2018-06-30 Add 52.15%0.28%$77.48 - $87.83 $ 90.609%651,133
Ken Fisher 2018-06-30 Add 4.51%$77.48 - $87.83 $ 90.609%226,743
Robert Olstein 2018-06-30 Reduce -25.86%0.31%$77.48 - $87.83 $ 90.609%86,000
Mario Gabelli 2018-06-30 Add 1.77%$77.48 - $87.83 $ 90.609%23,744
Dodge & Cox 2018-03-31 Add 2.39%0.03%$76.55 - $87.26 $ 90.6010%18,721,632
Barrow, Hanley, Mewhinney & Strauss 2018-03-31 Reduce -2.92%0.06%$76.55 - $87.26 $ 90.6010%15,240,620
HOTCHKIS & WILEY 2018-03-31 Add 55.70%0.44%$76.55 - $87.26 $ 90.6010%3,862,825
T Rowe Price Equity Income Fund 2018-03-31 Add 3.75%0.05%$76.55 - $87.26 $ 90.6010%3,320,000
Joel Greenblatt 2018-03-31 Add 109.50%0.25%$76.55 - $87.26 $ 90.6010%427,957
Ken Fisher 2018-03-31 Add 32.13%$76.55 - $87.26 $ 90.6010%216,956
Robert Olstein 2018-03-31 Reduce -0.85%0.01%$76.55 - $87.26 $ 90.6010%116,000
Mario Gabelli 2018-03-31 Reduce -20.41%$76.55 - $87.26 $ 90.6010%23,332
First Eagle Investment 2018-03-31 Sold Out $76.55 - $87.26 $ 90.6010%0
Dodge & Cox 2017-12-31 Add 50.53%0.38%$76.93 - $83.5 $ 90.6013%18,284,758
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -5.28%0.1%$76.93 - $83.5 $ 90.6013%15,698,567
Vanguard Health Care Fund 2017-12-31 Reduce -6.67%0.18%$76.93 - $83.5 $ 90.6013%15,408,784
T Rowe Price Equity Income Fund 2017-12-31 Add 3.23%0.04%$76.93 - $83.5 $ 90.6013%3,200,000
Bill Nygren 2017-12-31 Add 30.74%0.32%$76.93 - $83.5 $ 90.6013%3,190,000
HOTCHKIS & WILEY 2017-12-31 Add 10.91%0.07%$76.93 - $83.5 $ 90.6013%2,480,897
Joel Greenblatt 2017-12-31 Reduce -35.54%0.13%$76.93 - $83.5 $ 90.6013%204,272
Ken Fisher 2017-12-31 Reduce -13.08%$76.93 - $83.5 $ 90.6013%164,198
Robert Olstein 2017-12-31 Add 5.41%0.06%$76.93 - $83.5 $ 90.6013%117,000
Mario Gabelli 2017-12-31 Add 23.06%$76.93 - $83.5 $ 90.6013%29,314
NWQ Managers 2017-12-31 Sold Out $76.93 - $83.5 $ 90.6013%0
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -15.80%0.42%$77.71 - $88.9 $ 90.609%16,574,247
Dodge & Cox 2017-09-30 Add 4.86%0.04%$77.71 - $88.9 $ 90.609%12,147,095
T Rowe Price Equity Income Fund 2017-09-30 Add 14.53%0.15%$77.71 - $88.9 $ 90.609%3,100,000
HOTCHKIS & WILEY 2017-09-30 Add 0.41%$77.71 - $88.9 $ 90.609%2,236,797
Joel Greenblatt 2017-09-30 Reduce -28.21%0.16%$77.71 - $88.9 $ 90.609%316,892
Ken Fisher 2017-09-30 Add 2.80%$77.71 - $88.9 $ 90.609%188,912
Robert Olstein 2017-09-30 Add 21.78%0.2%$77.71 - $88.9 $ 90.609%111,000
Mario Gabelli 2017-09-30 Reduce -7.21%$77.71 - $88.9 $ 90.609%23,820
NWQ Managers 2017-09-30 Reduce -2.71%$77.71 - $88.9 $ 90.609%3,339
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:ABT, NYSE:SYK, NAS:ISRG, NYSE:BSX, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B » details
Traded in other countries:MDT.Argentina, MDTC34.Brazil, 2M6.Germany, MDTN.Mexico, MDT.Switzerland, 0Y6X.UK,
Headquarter Location:Ireland
Medtronic PLC is a medical technology company. It primarily manufacture and sell device-based medical therapies. It operates in Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies and Diabetes segments.

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for about 45% of the company's total sales.

Guru Investment Theses on Medtronic PLC

Jeff Auxier Comments on Medtronic - Aug 03, 2017

Deeply oversold in 2016 political uncertainties, the world's largest standalone medical technology company rebounded sharply for the quarter. A leader in biomedical devices, they sold their medical supplies business for $6.1 billion and will pay down debt and repurchase shares.


From Jeff Auxier (Trades, Portfolio)'s second-quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Medtronic plc - May 09, 2017

Medtronic is a leader in implantable biomedical devices. Back in 2001 the stock traded at 37.5 times earnings and this past quarter traded down to 13 times earnings with a fortress balance sheet and a 7% free cash flow yield. They continue to be a leader in medical technology as their world’s smallest pacemaker, Micra, accelerates US sales driving pacemaker market growth. They generate over $5 billion in free cash flow annually.

From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about Medtronic PLC

Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund Health care-focused fund releases 2nd-quarter portfolio
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed seven new positions when it released its second-quarter portfolio this week. Read more...
5 Companies Hit 52-Week Highs Medtronic, Waste Management, Williams Partners, Mosaic and Praxair achieve annual milestone
According to GuruFocus' list of 52-week highs, these stocks have reached their 52-week highs. Read more...
United Therapeutics Announces FDA Approval Of The Implantable System For Remodulin®
Market Trends Toward New Normal in Applied Optoelectronics, Integra LifeSciences, Medtronic, Workhorse Group, Platform Specialty Products, and Career Education — Emerging Consolidated Expectations, Analyst Ratings
Medtronic Launches the MiniMed(TM) 670G System Performance Guarantee for Payers and Employers
MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients
Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commercially Available
Medtronic Receives FDA Approval of New Pediatric Indication for the MiniMed(TM) 670G Hybrid Closed Loop System in Children Ages 7-13
Detailed Research: Economic Perspectives on Medtronic, NVIDIA, NutriSystem, AmTrust Financial Services, Kratos Defense & Security Solutions, and Envision Healthcare — What Drives Growth in Today's Competitive Landscape
Medtronic Study Confirms Feasibility of New Extravascular Approach to ICD Therapy

Ratios

vs
industry
vs
history
PE Ratio 40.09
MDT's PE Ratio is ranked lower than
66% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. MDT: 40.09 )
Ranked among companies with meaningful PE Ratio only.
MDT' s PE Ratio Range Over the Past 10 Years
Min: 10.17  Med: 21.23 Max: 54.09
Current: 40.09
10.17
54.09
Forward PE Ratio 17.67
MDT's Forward PE Ratio is ranked higher than
85% of the 52 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. MDT: 17.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 40.09
MDT's PE Ratio without NRI is ranked lower than
65% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.17 vs. MDT: 40.09 )
Ranked among companies with meaningful PE Ratio without NRI only.
MDT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.17  Med: 21.23 Max: 54.09
Current: 40.09
10.17
54.09
Price-to-Owner-Earnings 31.86
MDT's Price-to-Owner-Earnings is ranked higher than
64% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 32.03 vs. MDT: 31.86 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MDT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.24  Med: 18.92 Max: 37.87
Current: 31.86
9.24
37.87
PB Ratio 2.42
MDT's PB Ratio is ranked higher than
62% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. MDT: 2.42 )
Ranked among companies with meaningful PB Ratio only.
MDT' s PB Ratio Range Over the Past 10 Years
Min: 1.78  Med: 2.57 Max: 5.57
Current: 2.42
1.78
5.57
PS Ratio 4.13
MDT's PS Ratio is ranked lower than
55% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.15 vs. MDT: 4.13 )
Ranked among companies with meaningful PS Ratio only.
MDT' s PS Ratio Range Over the Past 10 Years
Min: 1.92  Med: 3.53 Max: 5.18
Current: 4.13
1.92
5.18
Price-to-Free-Cash-Flow 34.11
MDT's Price-to-Free-Cash-Flow is ranked higher than
52% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.44 vs. MDT: 34.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MDT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.18  Med: 14.49 Max: 34.11
Current: 34.11
9.18
34.11
Price-to-Operating-Cash-Flow 26.34
MDT's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 20.01 vs. MDT: 26.34 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MDT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.13  Med: 12.69 Max: 26.34
Current: 26.34
8.13
26.34
EV-to-EBIT 20.10
MDT's EV-to-EBIT is ranked higher than
59% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.76 vs. MDT: 20.10 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.6  Med: 15.75 Max: 31
Current: 20.1
8.6
31
EV-to-EBITDA 14.49
MDT's EV-to-EBITDA is ranked higher than
61% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 18.14 vs. MDT: 14.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 13.1 Max: 23.6
Current: 14.49
7.3
23.6
EV-to-Revenue 4.58
MDT's EV-to-Revenue is ranked lower than
57% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 3.73 vs. MDT: 4.58 )
Ranked among companies with meaningful EV-to-Revenue only.
MDT' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.3  Med: 3.5 Max: 6.4
Current: 4.58
2.3
6.4
PEG Ratio 6.08
MDT's PEG Ratio is ranked lower than
84% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. MDT: 6.08 )
Ranked among companies with meaningful PEG Ratio only.
MDT' s PEG Ratio Range Over the Past 10 Years
Min: 1.09  Med: 3.87 Max: 43.2
Current: 6.08
1.09
43.2
Shiller PE Ratio 30.33
MDT's Shiller PE Ratio is ranked higher than
74% of the 58 Companies
in the Global Medical Devices industry.

( Industry Median: 49.95 vs. MDT: 30.33 )
Ranked among companies with meaningful Shiller PE Ratio only.
MDT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.49  Med: 23.05 Max: 38.58
Current: 30.33
14.49
38.58
Current Ratio 2.28
MDT's Current Ratio is ranked lower than
52% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. MDT: 2.28 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.37 Max: 4.52
Current: 2.28
0.88
4.52
Quick Ratio 1.92
MDT's Quick Ratio is ranked higher than
52% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. MDT: 1.92 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.91 Max: 4.09
Current: 1.92
0.69
4.09
Days Inventory 143.86
MDT's Days Inventory is ranked lower than
51% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 143.61 vs. MDT: 143.86 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 133.79  Med: 142.57 Max: 164.01
Current: 143.86
133.79
164.01
Days Sales Outstanding 72.96
MDT's Days Sales Outstanding is ranked lower than
53% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 69.21 vs. MDT: 72.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.69  Med: 79.94 Max: 92.09
Current: 72.96
68.69
92.09
Days Payable 65.62
MDT's Days Payable is ranked higher than
59% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. MDT: 65.62 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 39.63  Med: 60.67 Max: 93.14
Current: 65.62
39.63
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.08
MDT's Dividend Yield % is ranked higher than
83% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. MDT: 2.08 )
Ranked among companies with meaningful Dividend Yield % only.
MDT' s Dividend Yield % Range Over the Past 10 Years
Min: 0.83  Med: 2.03 Max: 2.93
Current: 2.08
0.83
2.93
Dividend Payout Ratio 0.81
MDT's Dividend Payout Ratio is ranked higher than
71% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 0.32 vs. MDT: 0.81 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MDT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.29  Med: 0.39 Max: 0.81
Current: 0.81
0.29
0.81
3-Year Dividend Growth Rate 14.70
MDT's 3-Year Dividend Growth Rate is ranked higher than
64% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 9.70 vs. MDT: 14.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MDT' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 7.6  Med: 16.4 Max: 30.2
Current: 14.7
7.6
30.2
Forward Dividend Yield % 2.21
MDT's Forward Dividend Yield % is ranked higher than
82% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. MDT: 2.21 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.85
MDT's 5-Year Yield-on-Cost % is ranked higher than
84% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. MDT: 3.85 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MDT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.55  Med: 3.79 Max: 5.47
Current: 3.85
1.55
5.47
3-Year Average Share Buyback Ratio 1.60
MDT's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. MDT: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.3  Med: 0 Max: 2.5
Current: 1.6
-11.3
2.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.35
MDT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. MDT: 1.35 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MDT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.77  Med: 1.92 Max: 6.95
Current: 1.35
0.77
6.95
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.75
MDT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
85% of the 27 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. MDT: 3.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MDT' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.72  Med: 1.52 Max: 3.7
Current: 3.75
0.72
3.7
Price-to-Median-PS-Value 1.16
MDT's Price-to-Median-PS-Value is ranked lower than
54% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. MDT: 1.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.14 Max: 3.58
Current: 1.16
0.48
3.58
Price-to-Peter-Lynch-Fair-Value 6.64
MDT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
94% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MDT: 6.64 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MDT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.11  Med: 2.12 Max: 6.64
Current: 6.64
1.11
6.64
Earnings Yield (Greenblatt) % 4.98
MDT's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.74 vs. MDT: 4.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.2  Med: 6.3 Max: 11.6
Current: 4.98
3.2
11.6
Forward Rate of Return (Yacktman) % 10.05
MDT's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.60 vs. MDT: 10.05 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MDT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4  Med: 10.3 Max: 19.8
Current: 10.05
4
19.8

More Statistics

Revenue (TTM) (Mil) $29,953.00
EPS (TTM) $ 2.26
Beta0.76
Volatility15.48%
52-Week Range $76.41 - 91.50
Shares Outstanding (Mil)1,351.71

Analyst Estimate

Apr19 Apr20
Revenue (Mil $) 30,800 31,971
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 3.49 5.56
EPS without NRI ($) 3.49 5.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.12%
Dividends per Share ($) 1.97

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}